3 Out-of-Favor Stocks We Steer Clear Of

Rock-bottom prices don't always mean rock-bottom businesses. The stocks we're examining today have all touched their 52-week lows, creating a classic investor's dilemma: bargain opportunity or value trap?

Price charts only tell part of the story. Our team at StockStory evaluates each company's underlying fundamentals to separate temporary setbacks from structural declines. Keeping that in mind, here are three stocks where the skepticism is well-placed and some better opportunities to consider.

One-Month Return: -32.3%

Delighting customers since its inception in 1951, Jack in the Box (NASDAQ:JACK) is a distinctive fast-food chain known for its bold flavors, innovative menu items, and quirky marketing.

Why Should You Dump JACK?

Poor same-store sales performance over the past two years indicates it’s having trouble bringing new diners into its restaurants

Costs have risen faster than its revenue over the last year, causing its operating margin to decline by 9.3 percentage points

High net-debt-to-EBITDA ratio of 11× could force the company to raise capital at unfavorable terms if market conditions deteriorate

Jack in the Box is trading at $11.38 per share, or 3x forward P/E. Dive into our free research report to see why there are better opportunities than JACK.

One-Month Return: -25.5%

With a primary focus on soda but also a presence in energy drinks and teas, Zevia (NYSE:ZVIA) is a better-for-you beverage company.

Why Does ZVIA Give Us Pause?

Products fail to spark excitement with consumers, as seen in its flat sales over the last three years

Subscale operations are evident in its revenue base of $161.3 million, meaning it has fewer distribution channels than its larger rivals

Poor expense management has led to operating margin losses

At $1.24 per share, Zevia trades at 0.5x forward price-to-sales. Check out our free in-depth research report to learn more about why ZVIA doesn’t pass our bar.

One-Month Return: -13.3%

Founded in 1863 by a group of New York businessmen during the Civil War era, MetLife (NYSE:MET) is a global financial services company that provides insurance, annuities, employee benefits, and asset management services to individuals and businesses worldwide.

Why Do We Think MET Will Underperform?

Net premiums earned only expanded by 2.8% annually over the last five years, trailing its insurance peers as its scale limited incremental business

Earnings growth over the last two years fell short of the peer group average as its EPS only increased by 10.3% annually

Policy losses and capital returns have eroded its book value per share this cycle as its book value per share declined by 12.3% annually over the last five years

MetLife’s stock price of $68.60 implies a valuation ratio of 1.6x forward P/B. To fully understand why you should be careful with MET, check out our full research report (it’s free).

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it's flagging for this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.

Scroll to Top